Search

Your search keyword '"Bizzarri, C"' showing total 296 results
Start Over Author "Bizzarri, C" Language english
296 results on '"Bizzarri, C"'

2. Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients

Author

Garelli, S., Dalla Costa, M., Sabbadin, C., Barollo, S., Rubin, B., Scarpa, R., Masiero, S., Fierabracci, A., Bizzarri, C., Crinò, A., Cappa, M., Valenzise, M., Meloni, A., De Bellis, A. M., Giordano, C., Presotto, F., Perniola, R., Capalbo, D., Salerno, M. C., Stigliano, A., Radetti, G., Camozzi, V., Greggio, N. A., Bogazzi, F., Chiodini, I., Pagotto, U., Black, S. K., Chen, S., Rees Smith, B., Furmaniak, J., Weber, G., Pigliaru, F., De Sanctis, L., Scaroni, C., and Betterle, C.

Published
2021
Full Text
View/download PDF

16. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene

Author

Tonini, G., Bizzarri, C., Bonfanti, R., Vanelli, M., Cerutti, F., Faleschini, E., Meschi, F., Prisco, F., Ciacco, E., Cappa, M., Torelli, C., Cauvin, V., Tumini, S., Iafusco, D., Barbetti, F., and Early-Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology

Published
2006
Full Text
View/download PDF

24. XK-Aprosencephaly and Related Entities

Author

Renzetti, G., Villani, A., Bizzarri, C., Chessa, L., Vignati, E., Gianotti, A., Cappa, M., Szakacs, Juliana, Townsend, Jeanette J., Miller, Mark E., Opitz, John M., Kennedy, Anne M., and Byrne, Janice L.

Published
2005
Full Text
View/download PDF

26. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study

Author

Bowman P., Sulen A., Barbetti F., Beltrand J., Svalastoga P., Codner E., Tessmann E. H., Juliusson P. B., Skrivarhaug T., Pearson E. R., Flanagan S. E., Babiker T., Thomas N. J., Shepherd M. H., Ellard S., Klimes I., Szopa M., Polak M., Iafusco D., Hattersley A. T., Njolstad P. R., Aisenberg J., Akkurt I., Abdul-Latif H., Al-Abdullah A., Barak L., Van Den Bergh J., Bertrand A. -M., Bizzarri C., Bonfanti R., Bruel H., Burrows A., Cadario F., Cameron F. J., Carson D., Cartigny M., Cauvin V., Cave H., Chakera A., Chetan R., Chiari G., Couch B., Coutant R., Cummings E., Dankovcikova A., Davis L., Deiss D., Delvecchio M., Faleschini E., Fauret A. -L., Finn R., Ford T., Franco E. D., Gallen B. D., Gasperikova D., Guntamukkala P., Hakeem V., Hasegawa S., Hathout E. H., Heffernan E., Hill D., Ho J., Hoarau M., Holl R., Hoddinott R., Houghton J., Howard N., Hughes N., Hunter I., Hogasen A. K., Kuulasmaa H., Ioacara S., Iotova V., Irgens H., Jaap A., Jones K., Kapellen T., Kaufman E., Klinge A., Klupa T., Krishnaswamy R., Lafferty T., LeGault L., Lambert P., Malecki M. T., Malievsky O., Mathew R., Mathews F., McVie R., Menzel U., Metz C., Meulen J. V. D., Modgil G., Mul D., Muther S., Nuboer R., O'Connell S. M., O'Riordan S., Palko M., Patel K. A., Pesavento R., Piccinno E., Pillai J. K., Pruhova S., Punthakee Z., Rabbone I., Raile K., Rincon M., Rose D., Sanchez J., Sandereson S., Saxena V., Schebek M., Schmidt D., Shehadeh N., Shiels J. P. H., Silva J. M. C. L., Stanik J., Tinklin T., Tjora E., Tumini S., Tuomi T., Uehara A., Velde R. V. D., Vermeulen G., Visser U., Voorhoeve P., Walker J., Weill J., Weisner T., Werner A., Williams T., Woodhead H., oddegard R., Bowman, Pamela, Sulen, Åsta, Barbetti, Fabrizio, Beltrand, Jacque, Svalastoga, Pernille, Codner, Ethel, Tessmann, Ellen H, Juliusson, Petur B, Skrivarhaug, Torild, Pearson, Ewan R, Flanagan, Sarah E, Babiker, Tarig, Thomas, Nicholas J, Shepherd, Maggie H, Ellard, Sian, Klimes, Iwar, Szopa, Magdalena, Polak, Michel, Iafusco, Dario, Hattersley, Andrew T, Njølstad, Pål R, Aisenberg, Javier, Akkurt, Ilker, Abdul-Latif, Hussein, Al-Abdullah, Anee, Barak, Lubomir, Van Den Bergh, Joop, Bertrand, Anne-Marie, Bizzarri, Carla, Bonfanti, Riccardo, Bruel, Henri, Burrows, Anthony, Cadario, Francesco, Cameron, Fergus J., Carson, Denni, Cartigny, Maryse, Cauvin, Vittoria, Cave, Helene, Chakera, Ali, Chetan, Ravi, Chiari, Giovanni, Couch, Bob, Coutant, Régi, Cummings, Elizabeth, Dankovcikova, Adriana, Davis, Liz, Deiss, Dorothee, Delvecchio, Maurizio, Faleschini, Elena, Fauret, Anne-Laure, Finn, Roisin, Ford, Tamsin, Franco, Elisa De, Gallen, Bastian De, Gasperíková, Daniela, Guntamukkala, Padma, Hakeem, Vaseem, Hasegawa, Shinji, Hathout, Eba H., Heffernan, Emmeline, Hill, David, Ho, Josephine, Hoarau, Marie, Holl, Reinhard, Hoddinott, Rebecca, Houghton, Jane, Howard, Neville, Hughes, Natalie, Hunter, Ian, Høgåsen, Anne Kirsti, Kuulasmaa, Helena, Iocara, Sorin, Iotova, Violeta, Irgens, Henrik, Jaap, Alan, Jones, Kenneth, Kapellen, Thoma, Kaufman, Ellen, Klinge, Andrea, Klupa, Tomasz, Krishnaswamy, Ramaiyer, Lafferty, Tony, Legault, Laurent, Lambert, Paul, Malecki, Maciej T, Malievsky, Olag, Mathew, Revi, Mathews, France, Mcvie, Robert, Menzel, Ulrike, Metz, Chantale, Meulen, John Van Der, Modgil, Gita, Mul, Dick, Muther, Silvia, Nuboer, Roo, O'Connell, Susan M., O'Riordan, Stephen, Palko, Miroslav, Patel, Kashyap Amratlal, Pesavento, Roberta, Piccinno, Elvira, Pillai, Janani Kumaraguru, Pruhova, Stephanka, Punthakee, Zubin, Rabbone, Ivana, Raile, Klemen, Rincon, Marielisa, Rose, Danette, Sanchez, Janine, Sandereson, Susan, Saxena, Vinay, Schebek, Martin, Schmidt, Dorothee, Shehadeh, Naim, Shiels, Julian P. H., Silva, Jose M. C. L, Stanik, Juraj, Tinklin, Tracy, Tjora, Erling, Tumini, Stefano, Tuomi, Tiinamaija, Uehara, Akiko, Velde, Robert Van der, Vermeulen, Guido, Visser, Uma, Voorhoeve, Paul, Walker, Jan, Weill, Jaque, Weisner, Tobia, Werner, Andrea, Williams, Toni, Woodhead, Helen, Øddegård, Rønnaug, Bowman, P., Sulen, A., Barbetti, F., Beltrand, J., Svalastoga, P., Codner, E., Tessmann, E. H., Juliusson, P. B., Skrivarhaug, T., Pearson, E. R., Flanagan, S. E., Babiker, T., Thomas, N. J., Shepherd, M. H., Ellard, S., Klimes, I., Szopa, M., Polak, M., Iafusco, D., Hattersley, A. T., Njolstad, P. R., Aisenberg, J., Akkurt, I., Abdul-Latif, H., Al-Abdullah, A., Barak, L., Van Den Bergh, J., Bertrand, A. -M., Bizzarri, C., Bonfanti, R., Bruel, H., Burrows, A., Cadario, F., Cameron, F. J., Carson, D., Cartigny, M., Cauvin, V., Cave, H., Chakera, A., Chetan, R., Chiari, G., Couch, B., Coutant, R., Cummings, E., Dankovcikova, A., Davis, L., Deiss, D., Delvecchio, M., Faleschini, E., Fauret, A. -L., Finn, R., Ford, T., Franco, E. D., Gallen, B. D., Gasperikova, D., Guntamukkala, P., Hakeem, V., Hasegawa, S., Hathout, E. H., Heffernan, E., Hill, D., Ho, J., Hoarau, M., Holl, R., Hoddinott, R., Houghton, J., Howard, N., Hughes, N., Hunter, I., Hogasen, A. K., Kuulasmaa, H., Ioacara, S., Iotova, V., Irgens, H., Jaap, A., Jones, K., Kapellen, T., Kaufman, E., Klinge, A., Klupa, T., Krishnaswamy, R., Lafferty, T., Legault, L., Lambert, P., Malecki, M. T., Malievsky, O., Mathew, R., Mathews, F., Mcvie, R., Menzel, U., Metz, C., Meulen, J. V. D., Modgil, G., Mul, D., Muther, S., Nuboer, R., O'Connell, S. M., O'Riordan, S., Palko, M., Patel, K. A., Pesavento, R., Piccinno, E., Pillai, J. K., Pruhova, S., Punthakee, Z., Rabbone, I., Raile, K., Rincon, M., Rose, D., Sanchez, J., Sandereson, S., Saxena, V., Schebek, M., Schmidt, D., Shehadeh, N., Shiels, J. P. H., Silva, J. M. C. L., Stanik, J., Tinklin, T., Tjora, E., Tumini, S., Tuomi, T., Uehara, A., Velde, R. V. D., Vermeulen, G., Visser, U., Voorhoeve, P., Walker, J., Weill, J., Weisner, T., Werner, A., Williams, T., Woodhead, H., and Oddegard, R.

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine
Abstract

Background: KCNJ11 mutations cause permanent neonatal diabetes through pancreatic ATP-sensitive potassium channel activation. 90% of patients successfully transfer from insulin to oral sulfonylureas with excellent initial glycaemic control; however, whether this control is maintained in the long term is unclear. Sulfonylurea failure is seen in about 44% of people with type 2 diabetes after 5 years of treatment. Therefore, we did a 10-year multicentre follow-up study of a large international cohort of patients with KCNJ11 permanent neonatal diabetes to address the key questions relating to long-term efficacy and safety of sulfonylureas in these patients. Methods: In this multicentre, international cohort study, all patients diagnosed with KCNJ11 permanent neonatal diabetes at five laboratories in Exeter (UK), Rome (Italy), Bergen (Norway), Paris (France), and Krakow (Poland), who transferred from insulin to oral sulfonylureas before Nov 30, 2006, were eligible for inclusion. Clinicians collected clinical characteristics and annual data relating to glycaemic control, sulfonylurea dose, severe hypoglycaemia, side-effects, diabetes complications, and growth. The main outcomes of interest were sulfonylurea failure, defined as permanent reintroduction of daily insulin, and metabolic control, specifically HbA 1c and sulfonylurea dose. Neurological features associated with KCNJ11 permanent neonatal diabetes were also assessed. This study is registered with ClinicalTrials.gov, number NCT02624817. Findings: 90 patients were identified as being eligible for inclusion and 81 were enrolled in the study and provided long-term (>5·5 years cut-off) outcome data. Median follow-up duration for the whole cohort was 10·2 years (IQR 9·3–10·8). At most recent follow-up (between Dec 1, 2012, and Oct 4, 2016), 75 (93%) of 81 participants remained on sulfonylurea therapy alone. Excellent glycaemic control was maintained for patients for whom we had paired data on HbA 1c and sulfonylurea at all time points (ie, pre-transfer [for HbA 1c ], year 1, and most recent follow-up; n=64)—median HbA 1c was 8·1% (IQR 7·2–9·2; 65·0 mmol/mol [55·2–77·1]) before transfer to sulfonylureas, 5·9% (5·4–6·5; 41·0 mmol/mol [35·5–47·5]; p

Published
2018

30. Combined therapy with insulin and rGH in thirteen Italian patients with type 1 diabetes (T1DM) and growth disorders

Author

Zucchini, S., Pozzobon, G., Bonfanti, R., Vannelli, S., Rabbone, I., Maghnie, M., Bizzarri, C., Tumini, S., Lenzi, L., Maggio, M. C., Iafusco, D., Marigliano, M., Cherubini, V., Iughetti, Lorenzo, Zucchini, S, Pozzobon, G, Bonfanti, R, Vannelli, S, Rabbone, I, Maghnie, M, Bizzarri, C, Tumini, S, Lenzi, L, Maggio, M C, Iafusco, D, Marigliano, M, Cherubini, V, and Iughetti, L

Subjects
Settore MED/38 - Pediatria Generale E Specialistica, type 1 diabetes, T1DM, GH, Insulin, GH
Abstract

Background: Combined GH and insulin therapy are rarely prescribed in pediatric pts because the association of GHD and T1DM is rare and maybe for the difficulties in managing a double therapy with opposite effects on glucose metabolism. Objective and hypotheses: To investigate on the attitude of pediatric endo-diabetologists in treating these pts. Methods: Data were collected from over 50 centres belonging to the ISPED. The inclusion criterion was based on the double therapy for at least 6 months with insulin due to T1DM, and rGH, due to growth impairment. Results: Most centres stated that the use of combined therapy was considered uncomfortable and frequently avoided, whereas 10 centres reported the treatment of 13 pts (7M, 6F). In 7 pts T1DM was the first diagnosis (age at onset from 1.5 to 9.5 yrs) and they were treated with insulin (group 1) and with rGH subsequently (after 0.5-9.75 yrs) due to idiopathic GHD in 4 pts, Turner s. in 1 pt, Leri-Weill s. in 1 pt and bone dysplasia in 1 pt. In 6 pts rGH therapy was started first (age at start 2.5-12 yrs) due to idiopathic GHD in 4 pts, organic GHD in 1 pt and Turner s. in 1 pt. Height SDS at the start of rGH therapy ranged from -2.5 to -3.9. Longest duration of rGH therapy was 7 yrs and 5 pts are still treated. Insulin schedule was with MDI in 10 pts and with CSII in the remaining 3. In the 7 pts of group 1, mean insulin dose increased during the first 6 months after rGH start from 0.68 to 1.06 U/kg (p=0.03). HbA1c was not modified after 6 months compared to the baseline value (7.62±0.8 vs 7.76±0.57). In the pt with Leri-Weill s. rGH therapy was stopped due to impaired metabolic control. No significant side-effects during the treatment were reported. Conclusions: Double therapy with insulin and GH is uncommonly performed in pediatric patients. Despite a higher insulin requirement, metabolic control in patients with T1DM was not impaired significantly by the simultaneous treatment. Our data suggest that GH is not an absolute contraindication for treatment of children with T1DM and growth disorders.

Published
2012

31. Minimal Incidence of neonatal /infancy onset diabetes in Italy is 1:90000 live births

Author

Iafusco D, Massa O, Pasquino B, Colombo C, Iughetti L, Bizzarri C, Mammi C, Lo Presti D, Suprani T, Schiaffini R, Nichols CG, Russo L, Grasso V, Meschi F, Bonfanti R, Brescianini S, Barbetti F., Iafusco, D, Massa, O, Pasquino, B, Colombo, C, Iughetti, L, Bizzarri, C, Mammi, C, Lo Presti, D, Suprani, T, Schiaffini, R, Nichols, Cg, Russo, L, Grasso, V, Meschi, F, Bonfanti, R, Brescianini, S, and Barbetti, F.

Published
2011

32. Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation

Author

Bizzarri, C., Pinto, R. M., Ciccone, S., Brescia, L. P., Locatelli, F., and Cappa, M.

Subjects
Male, Transplantation Conditioning, Adolescent, Hematopoietic stem cell transplantation, Comorbidity, Hypothyroidism, Non-alcoholic Fatty Liver Disease, Risk Factors, Glucose Intolerance, Body Fat Distribution, Humans, Prospective Studies, Survivors, Obesity, cancer survivor, child, hematopoietic stem cell transplantation, insulin resistance, metabolic syndrome, obesity, Child, Anthropometry, Hypogonadism, Body Weight, Infant, Insulin resistance, Metabolic syndrome, Hormones, Causality, Cross-Sectional Studies, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Cardiovascular Diseases, Case-Control Studies, Child, Preschool, Hematologic Neoplasms, Cancer survivor, Disease Progression, Female, Whole-Body Irradiation
Abstract

It is unclear whether there is a causative relationship between the development of metabolic syndrome (MS) and increased risk of early cardiovascular morbidity in patients receiving hematopoietic stem cell transplantation (HSCT) during childhood. Early identification of risk factors associated with insulin resistance, MS, and abnormal glucose tolerance during childhood or adolescence in these patients could represent a useful tool for preventing cardiovascular disorders.In a single-center, prospective, descriptive, cross-sectional study, we studied 45 survivors of hematological malignancies (age: 13.9 ± 4.8 years) treated with HSCT before the age of 18 years and 90 matched healthy controls. We collected clinical, imaging, and laboratory data including oral glucose tolerance test (OGTT).7/45 patients (15.6%) showed abnormal glucose tolerance at OGTT, 1/45 (2.2%) was obese, and none fulfilled the criteria for MS. A waist/height ratio0.5 was associated with patients with abnormal glucose tolerance (85.7% of cases), compared to patients with normal glucose tolerance (42.1%) and controls (23.3%). In patients with abnormal glucose tolerance, use of total body irradiation (TBI) as conditioning regimen was more common, and time elapsed from HSCT was longer.Patients treated with HSCT may develop insulin resistance early after transplantation. They do not show overt obesity, but have redistribution of fat tissue with central fat accumulation. The main factors associated with increased metabolic risk are TBI and time from HSCT. Evaluation of MS and glucose tolerance should be part of hormonal follow-up, which should be routinely proposed to these patients.

Published
2015

37. Diabetes-related autoantibodies in children with acute lymphoblastic leukemia

Author

Bizzarri, C., Pinto, R. m., Pitocco, D., Astorri, E., Cappa, M., Hawa, M., Giannone, G., Palermo, A., Maddaloni, E., Leslie, Dr, Pozzilli, P., Altomare, M., Barchetta, Ilaria, Benevento, D., Beretta Anguissola, G., Buzzetti, Raffaella, Capizzi, M., Cappa, M. r., Cavallo, Maria Gisella, Cipolloni, L., Cipponeri, E., Costantino, F., Crino, A., Defeudis, G., Di Stasio, E., Fallucca, S., Fioriti, E., Ghirlanda, G., Guglielmi, C., Khazrai Yeganeh, M., Kyanvash, S., Lauria, A., Maggi, D., Manfrini, S., Maurizi, A. r., Moretti, C., Morviducci, L., Napoli, N., Patera, P., Portuesi, R., Schiaffini, R., Scrocca, R., Spera, S., Strollo, R., Suraci, C., Tubili, C., Tuccinardi, D., Valente, L., and Visalli, N.

Subjects
Male, medicine.medical_specialty, Diabetes Care Electronic Pages, Endocrinology, Diabetes and Metabolism, Glutamate decarboxylase, Radioimmunoassay, Pre B Lymphocyte, Internal medicine, Diabetes mellitus, Epidemiology, Internal Medicine, medicine, Diabetes Mellitus, Humans, Insulin, Online Letters: Observations, Child, Philadelphia 1 Chromosome, Autoantibodies, Acute Lymphoblastic Leukemia, Advanced and Specialized Nursing, Type 1 diabetes, business.industry, Glutamate Decarboxylase, Thyroid, Autoantibody, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Leukemia, medicine.anatomical_structure, Child, Preschool, Immunology, Etiology, Female, business
Abstract

Acute lymphoblastic leukemia (ALL) is the most common subtype of leukemia in children. Although ALL and type 1 diabetes appear to be biologically unrelated, there are common threads in both epidemiology and etiology. Rising incidence rates of both ALL (1) and type 1 diabetes (2) observed over recent decades in many Western countries seem to support common etiological factors (3). In the current study, we report on diabetes-related autoantibodies (Abs) in a group of patients with ALL. Thirty-four consecutive children (19 males and 15 females, mean age 6.2 ± 4.6 years) were referred to our institution in 2004 for newly diagnosed ALL. Patients were tested for Abs to islet and thyroid antigens. After the initial investigation and treatment, 31/34 (91%) patients (3 died in the mean time) were followedup for 6 years to evaluate the evolution of the autoimmune markers and progression toward type 1 diabetes. Glutamic acid decarboxylase (GAD) Abs by direct …

Published
2012

40. Blue eyes and fair skin as risk factors for type I diabetes

Author

Di Stasio, Enrico, Maggi, Daria, Berardesca, E, Marulli, Gc, Bizzarri, C, Lauria, A, Portuesi, R, Cavallo, Mg, Costantino, F, Buzzetti, R, Astorri, E, Pitocco, Dario, Songini, M, and Pozzilli, Paolo

Subjects
diabetes, Settore BIO/10 - BIOCHIMICA
Published
2011

41. Permanent diabetes during the first year of life: multiple gene screening in 54 patients

Author

Russo, L, Iafusco, D, Brescianini, S, Nocerino, V, Bizzarri, C, Toni, S, Cerutti, F, Monciotti, C, Pesavento, R, Iughetti, L, Bernanrdini, L, Bonfanti, R, Gargantini, L, Vanelli, M, AGUILAR BRYAN, L, Stazi, Ma, Grasso, V, Colombo, C, Barbetti, F, the EARLY DIABETES STUDY GROUP LERA, R, Cherubini, V, Fifi, Ar, Torelli, C, Frezza, E, Cavallo, L, Zucchini, S, Pasquino, B, Kaufmann, P, Frongia, P, Zedda, N, Ripoli, C, LA LOGGIA, A, LO PRESTI, D, Pocecco, M, Chiarelli, F, Tumini, S, DEL DONNO, M, DE MARCO MR, Lenzi, L, Lorini, R, D'Annunzio, G, Lombardo, F, Meschi, F, Franzese, A, Buono, P, Prisco, F, Cadario, F, Cardella, F, Calcaterra, V, DE GIORGI, G, Federico, Giovanni, Cappa, M, Sulli, N, MANCA BITTI ML, Delvecchio, M, Cotellessa, M, Rabbone, I, Cauvin, V, Bellizzi, M, Tonini, G, Salvatoni, A, and Pinelli, L.

Published
2011

44. No protective effect of calcitriol on β-cell function in recent-onset type 1 diabetes: The IMDIAB XIII trial

Author

Bizzarri, C., Pitocco, D., Napoli, N., Di Stasio, E., Maggi, D., Manfrini, S., Suraci, C., Cavallo, Maria Gisella, Cappa, M., Ghirlanda, G., Pozzilli, P., and Group, Imdiab

Subjects
Adult, Male, Advanced and Specialized Nursing, Glycated Hemoglobin A, Adolescent, C-Peptide, Calcitriol, Child, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemic Agents, Insulin, Insulin-Secreting Cells, Young Adult, Internal Medicine, Endocrinology, Diabetes and Metabolism, Diabetes and Metabolism, Endocrinology, Diabetes Mellitus, Type 1
Published
2010

45. Incidence of type 1 diabetes has doubled in Rome and the Lazio region in the 0- to 14-year age-group: A 6-year prospective study (2004-2009)

Author

Bizzarri, C., Patera, P. I., Arnaldi, C., Petrucci, S., Bitti, M. L. M., Scrocca, R., Manfrini, S., Portuesi, R., Buzzetti, Raffaella, Cappa, M., Pozzilli, P., and Immunotherapy Diabetes Imdiab Group

Subjects
Male, Pediatrics, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, Rome, Group A, Settore MED/13 - Endocrinologia, Diabetes mellitus, Internal Medicine, medicine, Diabetes Mellitus, Humans, Prospective Studies, Prospective cohort study, Child, Preschool, Advanced and Specialized Nursing, American diabetes association, Settore MED/38 - Pediatria Generale e Specialistica, Type 1 diabetes, diabetes, business.industry, Incidence (epidemiology), Autoantibody, Infant, Newborn, Infant, Italy, Child, Preschool, Diabetes Mellitus, Type 1, Incidence, Female, medicine.disease, Newborn, Lazio region, incidence, business, Type 1
Abstract

Incidence of type 1 diabetes is rising, especially among younger children (1,2). We evaluated type 1 diabetes incidence in the years 2004–2009 among subjects

Published
2010

46. Age-period-cohort analysis of 1990-2003 incidence time trends of childhood diabetes in Italy: the RIDI study

Author

Bruno, G, Maule, M, Merletti, F, Novelli, G, Falorni, A, Iannilli, A, Iughetti, Lorenzo, Altobelli, E, D'Annunzio, G, Piffer, S, Pozzilli, P, Iafusco, D, Songini, M, Roncarolo, F, Toni, S, Carle, F, Cherubini, V, Cerutti, F, Franchini, S, Bianchi, L, Lorini, R, Minuto, N, Sacco, S, Ramondetti, F, Predieri, Barbara, Reali, S, Medici, A, Biagioni, M, Gesuita, R, Santeusanio, F, De Giorgi, G, Visalli, N, Bizzarri, C, Chiarelli, F, Tumini, S, Prisco, F, Confetto, S, Frongia, P, and Marinaro, A.

Subjects
Cohort Studies, Type 1 diabetes, incidence
Published
2010

48. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI)

Author

Pitocco, D., Crino, A., Di Stasio, E., Manfrini, S., Guglielmi, C., Spera, S., Beretta Anguissola, G., Visalli, N., Suraci, C., Matteoli, M. C., Patera, I. P., Cavallo, Maria Gisella, Bizzarri, C., Pozzilli, P., and Group, Imdiab

Subjects
Blood Glucose, Male, Niacinamide, calcitriol, medicine.medical_specialty, Calcitriol, Adolescent, type 1 diabetes, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, nicotinamide, Pilot Projects, Bedtime, law.invention, chemistry.chemical_compound, Endocrinology, Randomized controlled trial, law, Diabetes mellitus, Internal medicine, Insulin-Secreting Cells, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Insulin, Type 1 diabetes, Nicotinamide, business.industry, medicine.disease, B vitamins, Diabetes Mellitus, Type 1, chemistry, Drug Therapy, Combination, Female, business, medicine.drug
Abstract

Background A number of recent studies underline the importance of vitamin D in the pathogenesis of Type 1 diabetes (T1D). Aims The aim of this study was to investigate whether supplementation with the active form of vitamin D (calcitriol) in subjects with recent-onset T1D protects residual pancreatic β-cell function and improves glycaemic control (HbA1c and insulin requirement). Methods In this open-label randomized trial, 70 subjects with recent-onset T1D, mean age 13.6 years ± 7.6 sd were randomized to calcitriol (0.25 µg on alternate days) or nicotinamide (25 mg/kg daily) and followed up for 1 year. Intensive insulin therapy was implemented with three daily injections of regular insulin + NPH insulin at bedtime. Results No significant differences were observed between calcitriol and nicotinamide groups in respect of baseline/stimulated C-peptide or HbA1c 1 year after diagnosis, but the insulin dose at 3 and 6 months was significantly reduced in the calcitriol group. Conclusions At the dosage used, calcitriol has a modest effect on residual pancreatic β-cell function and only temporarily reduces the insulin dose.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results